437 completed, 349 recruiting, 291 active not recruiting, 242 terminated. 1611 Phase 2, 428 Phase 1, 40 Phase 3.
Follow pembrolizumab: new trials by email Literature Review of pembrolizumab trials Research Report on pembrolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy Larotrectinib, Pembrolizumab - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 22 | 2027-03-01 | 2026-09-28 |
| A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck. INCA33890, Pembrolizumab - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Groupe Oncologie Radiotherapie Tete et Cou | 78 | 2027-02-01 | 2026-10-22 |
| A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy（NCCH2407/MK014） Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma | Phase 2 | Not yet recruiting | National Cancer Center, Japan | 32 | 2027-02-01 | 2026-11-03 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes | Phase 2 | Recruiting | Medical University of South Carolina | 55 | 2027-01-01 | 2026-10-15 |
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Canadian Cancer Trials Group | 160 | 2026-12-31 | 2026-10-27 |
| Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Exelixis | 60 | 2026-12-15 | 2026-09-29 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 30 | 2026-12-01 | 2026-10-26 |
| Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab - Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm | Phase 2 | Not yet recruiting | VA Office of Research and Development | 30 | 2026-12-01 | 2026-10-06 |
| Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma enfortumab vedotin and pembrolizumab (EV/P) - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | University of Florida | 39 | 2026-12-01 | 2026-09-14 |
| Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) Pembroluzimab, Observation - HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2026-12-01 | 2026-10-08 | |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-11-30 | 2026-11-03 |
| Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer Dexamethasone, Famotidine, Diphenhydramine - Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 17 | 2026-11-30 | 2026-11-03 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial Paclitaxel + Carboplatin, Pembrolizumab - Triple Negative Breast Cancer, Blood and Image Guided | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2026-11-05 | 2026-05-28 |
| A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer Enfortumab vedotin, Pembrolizumab - Muscle-invasive Bladder Urothelial Carcinoma | Phase 2 | Not yet recruiting | University of Utah | 25 | 2026-11-01 | 2026-09-16 |
Showing 20 of 1611. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (238) · Melanoma (171) · Squamous Cell Carcinoma of Head and Neck (151) · Breast Neoplasms (106) · Triple Negative Breast Neoplasms (101) · Neoplasm Metastasis (87) · Neoplasms (84) · Lung Neoplasms (81) · Head and Neck Neoplasms (79) · Colorectal Neoplasms (75) · Carcinoma, Renal Cell (72) · Parkinson Disease 4, Autosomal Dominant Lewy Body (71) · Ovarian Neoplasms (66) · Stomach Neoplasms (65) · Carcinoma, Transitional Cell (62)
Merck Sharp & Dohme LLC (91) · M.D. Anderson Cancer Center (59) · National Cancer Institute (NCI) (44) · Memorial Sloan Kettering Cancer Center (29) · Dana-Farber Cancer Institute (23) · Mayo Clinic (22) · Roswell Park Cancer Institute (17) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (15) · University of Chicago (15) · City of Hope Medical Center (14) · Emory University (14) · University of California, San Francisco (14) · University of Washington (14) · H. Lee Moffitt Cancer Center and Research Institute (13) · UNC Lineberger Comprehensive Cancer Center (13)
United States (1061) · Spain (219) · Italy (165) · France (164) · South Korea (162) · Australia (146) · China (143) · United Kingdom (138) · Germany (135) · Canada (126) · Poland (94) · Taiwan (84) · Japan (79) · Belgium (73) · Israel (72)
Alison Moskowitz, MD (5) · Salah-Eddin Al-Batran, Prof. Dr. (5) · Stergios Moschos, MD (4) · Charalampos Floudas, M.D. (3) · Douglas R Adkins, M.D. (3)
PMID 35101941, PMID 31395089, PMID 15800326, PMID 11698646, PMID 15771580, PMID 18565862, PMID 20516428, PMID 34754076, PMID 36648215, PMID 37699333, PMID 16227604, PMID 17360651, PMID 19188168, PMID 20636820, PMID 26712084, PMID 27093365, PMID 27718847, PMID 27745820, PMID 28271869, PMID 29395863, PMID 31029646, PMID 32305010, PMID 33096027, PMID 33416261, PMID 35387488, PMID 35623069, PMID 36852452, PMID 37598000, PMID 38321811, PMID 38816232, PMID 40135712, PMID 40341124, PMID 40668662, PMID 41698326, PMID 10704469, PMID 11015443, PMID 11282341, PMID 11282421, PMID 11602624, PMID 11784875, PMID 11910893, PMID 12091876, PMID 12218188, PMID 12242449, PMID 1244564, PMID 12538684, PMID 12695859, PMID 12721664, PMID 12778165, PMID 12806613
2023 (73), 2016 (24), 2018 (23), 2019 (22), 2025 (19), 2017 (18), 2015 (14), P30CA138292 (13), 2014 (10), P30CA060553 (10), P30CA015704 (9), U10CA180888 (7), P30CA012197 (6), P30CA033572 (6), U10CA180820 (6)